An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: A randomized, controlled trial

Journal of Drugs in Dermatology

Volumn 10, Issue 5, 2011, Pages 531-537

  Miller, Drew W ^a,b   Koch, Sarah B ^a,b   Yentzer, Brad A ^a,b   Clark, Adele R ^a,b   O'Neill, Jenna ^a,b   Fountain, Julie ^a,b   Weber, Teresa M ^a,b   Fleischer Jr , Alan B ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Beiersdorf Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPHOR HEALING OINTMENT; ATOPICLAIR; CERAMIDE; EPICERAM; GLYCYRRHETINIC ACID; NON PRESCRIPTION DRUG; PETROLEUM; PRESCRIPTION DRUG; TRIAMCINOLONE; UNCLASSIFIED DRUG; CHOLESTEROL; DERMATOLOGICAL AGENT; EMOLLIENT AGENT; FATTY ACID; MAS063DP; PETROLATUM; PLANT EXTRACT;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; ECONOMICS; FAT INTAKE; HOSPITALIZATION; INTRADERMAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; CERAMIDES; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; COST-BENEFIT ANALYSIS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DIETARY FATS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EMOLLIENTS; FATTY ACIDS; FEMALE; GLYCYRRHETINIC ACID; HUMANS; MALE; NONPRESCRIPTION DRUGS; PETROLATUM; PLANT EXTRACTS; PRESCRIPTION DRUGS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 80051637908     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol. 2000;43:649-655.
2. Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999;103:125-138. (Pubitemid 29063202)
3. Odom RB, James WD, Berger TG. Atopic dermatitis. Andrews' Diseases of the Skin/Clinical Dermatology. Philadelphia: WB Saunders; 2005:69-94.
4. Mancini, Anthony J, et al. The Socioeconomic Impact of Atopic Dermatitis in the United States: A Systemic Review. Ped Dermatol. 2008;25(1):1-6.
5. Draelos, Zoe D. An evaluation of prescription device moisturizers. Journal of Cosmetic Dermatology. 2009;8:40-43.
6. Eichenfield, Lawrence. Consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy. 2004:59(suppl 78):86-92.
7. Loden, Marie. Role of Topical Emollients and Moisturizers in the Treatment of Dry Skin Barrier Disorders. Am J Clin Dermatol. 2003:4(11):771-778.
8. Lucky AW, Leach AD, Laskarzewski P, et al. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Ped Dermatol. 1997;14:321-324. (Pubitemid 27332923)
9. FDA U.S. Food and Drug Administration: Medical Devices. 510(k) Clearances. Available at: http://www.fda.gov/medicaldevices/ productsandmedicalprocedures/deviceapprovalsandclearances/510kcl earances/default.htm. Accessed February 20, 2010.
10. Belloni G, Pinelli S, Veraldi S. A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair®) in the treatment of mild to moderate atopic dermatitis. Eur J Dermatol. 2005:15(1): 31-36. (Pubitemid 40254620)
11. Sugarman JL, Lawrence, CP. Efficacy of a Lipid-Based Barrier Repair Formulation in Moderate-to-Severe Pediatric Atopic Dermatitis. J Drugs Dermatol. 2009:8(12):1106-1111.
12. Boguniwicz, M, et al. MAS063DP is Effective Monotherapy for Mild to Moderate Atopic Dermatitis in Infants and Children: A Multicenter, Randomized, Vehicle-Controlled Study. J Pediatr. 2008:152(6):854-859.
13. Abramovits W, Boguniewicz M. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair®) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol. 2006:5(3):236-244.
14. Drugstore.com: Aquaphor Healing Ointment. Available at: http://www.drugstore.com/aquaphor-healing-ointment/qxp13123?fromsrch= aquaphor+healing+oinment. Accessed February 3, 2010.
15. Drugstore.com: Atopiclair. Available at: http://www.drugstore.com/ atopiclair/100gm-tube-cream/qxn29336010011.
16. Universaldrugstore.com: Epiceram. Available at: http://www. universaldrugstore.com/medications/epiceram. Accessed February 3, 2010.
17. Steele T, Pawaskar M, Balkrishnan R, Fleischer A, Feldman SR. Does cost-effectiveness play a role in clinical trials? Dermatol Ther. 2007;20(2):110-119. (Pubitemid 46817426)